Peptides DB
Research-centric peptide and protocol reference hub

Albiglutide record · updated 6h ago

Metabolic & appetiteSkin & aestheticsGrade A · human clinicalResearch use only
All 15 studiesJump to the evidenceCompare
What is Albiglutide used for?

Albiglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that was developed for the treatment of type 2 diabetes mellitus (T2DM). It functions by mimicking the action of the endogenous GLP-1 hormone, which is involved in glucose metabolism. Albiglutide enhances insulin secretion in response to elevated blood glucose levels, suppresses glucagon secretion, slows gastric emptying, and promotes satiety, thereby contributing to improved glycemic control and weight management.

How it works: GLP-1 receptor agonist

Primarily researched for · Metabolic & appetiteRoute · Subcutaneous injection

Development stage

where Albiglutide sits between preclinical work and regulatory approval
  1. 1Current
    Preclinical
    Animal / in-vitro work
  2. 2Not reached
    Phase 1
    Safety in humans
  3. 3Not reached
    Phase 2
    Efficacy signal
  4. 4Not reached
    Phase 3
    Confirmatory trials
  5. 5Not reached
    Approved
    Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus and 62 registered trials. It describes the research record, not a recommendation.

Identity
NameAlbiglutide
Chain length—
Molecular weight3,284.6 Da
FormulaC148H223N39O46
Structure typeNot established
ClassMetabolic
Research levelLimited Research
Discovered byThe Librarian · 2026

Mass and formula from PubChem CID 122173812. No verified residue count for this compound.

Pharmacology
MechanismGLP-1 receptor agonist
RouteSubcutaneous injection
Half-life~5 days
Time to peak1–3 days
Duration~7 days
Extraction confidence0.90
Effect profile · 0–5
These seven scores are generated by the Librarian — an autonomous agent running GPT-4o over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Sep 9, 2026. How this works →
Research stats
Total studies15
Human / animal / cellular9 / 0 / 0
Highest trial phase—
Years covered2023–2026
Latest study12d ago
Publication history
20232026
Research funding
—no NIH grants found
Safety signals
FAERS reports163
Serious AEs in animal work—
Community reports—
Positive —Neutral —Negative —
Records

Study register

15 rows · newest 12 shownOpen in the library →
StudyTypeYearSummary depth
Efficacy and Safety of GLP-1 Receptor Agonists on Combined Cardiovascular and Renal Outcomes in Patients With Chronic Kidney Disease: A Systematic Review and Meta-Analysis.
Finding16% reduction in MACE (HR 0.84, 95% CI 0.79-0.89; high certainty)
review2023Full text read0.90
Cardiovascular Efficacy of GLP-1 Receptor Agonists by Kidney Function: An Updated Meta-Analysis of Randomized Trials Including the SOUL Trial.
FindingPooled HR for MACE with eGFR ≥ 60 mL/min/1.73 m² was 0.83 (95% CI 0.77-0.90; p < 0.001; I² = 35.6%)
review2023Full text read0.90
Prevalence of Obesity and Related Conditions and GLP-1 Use in Medicare Fee-for-Service Beneficiaries.
Finding6.2% of Medicare FFS beneficiaries with Part D (n=16,474,786) had GLP-1 RAs.
Human2023Full text read0.80
Tirzepatide Is Associated With Improved Metabolic Outcomes in People With Type 1 Diabetes and Overweight or Obesity: A Retrospective Cohort Study.
Finding-10.01% ± 4.74% body weight reduction vs +0.69% ± 3.77% in controls, adj-p < 0.0001
Human2023Full text read0.80
Glucagon-like peptide-1 receptor agonists are associated with fewer venous thromboembolic events and limb complications in obese patients with chronic venous insufficiency.
FindingHR for acute DVT risk at 1 year was 0.54; 95% CI, 0.42-0.71; P < .001.
Human2026Full text read0.80
Association of Glucagon-Like Peptide-1 Receptor Analogues and Laryngeal Symptoms in Obese Adults.
FindingGLP-1RA therapy increased the 6-month risk of any laryngeal manifestations (OR 1.19, 95% CI 1.16-1.21; p<0.0001).
Human2023Full text read0.80
Effect of a Novel GLP-1 Analogue Ecnoglutide on the Pharmacokinetics of Rosuvastatin and Digoxin in Healthy Participants.
FindingGeometric mean ratio for rosuvastatin with ecnoglutide was 106% (94%, 120%)
Human2026Full text read0.80
Is there a risk for Semaglutide Misuse? Focus on the Food and Drug Administration-FDA Adverse Events Reporting System (FAERS) pharmacovigilance dataset
FindingPRR for 'drug abuse' for semaglutide was 4.05 (p<0.01).
Human2023Full text read0.80
Phenotype-based targeted treatment of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes
Finding≥5 mmol/mol HbA1c benefits associated with each drug class.
Human2023Full text read0.80
Is There a Risk for Semaglutide Misuse? Focus on the Food and Drug Administration-FDA Adverse Events Reporting System (FAERS) Pharmacovigilance Dataset
FindingPRR for 'drug abuse' with semaglutide was 4.05 (p<0.01).
Human2023Full text read0.80
Age- and sex- differences in efficacy of treatments for type 2 diabetes: Network meta-analysis of aggregate and individual level data
FindingSGLT2i reduced HbA1c by 0.5-1.0% overall compared to placebo.
Human2024Full text read0.80
Efficacy and Safety of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Ventricular Arrhythmias and Cardiovascular Events: A Disease-Stratified Network Meta-Analysis.
FindingOR 0.31, 95% CI 0.11-0.86 for lower VA risk with empagliflozin in the T2DM network.
review2023Full text read0.90

What people are saying

anecdotal · not evidence

Unverified first-hand accounts from public forums. These are not studies: nobody checked what was taken, whether it was what the label said, or what else was going on. They count for nothing in the evidence grade above and are shown because a reader searching Albiglutide will meet them anyway, and meeting them next to a graded evidence base is better than meeting them alone.

Community collection has not run yet, so this is an empty shelf rather than a quiet one — nothing has been read, and no conclusion about how much Albiglutide is discussed should be drawn from it.